HOME ABOUT US RESEARCH & DEVELOPMENT FOR PATIENTS NEWS AND EVENTS WHEN YOU EXPLORE NEW ANGLES YOU DISCOVER NEW HORIZONS 1 PATIENTS Read More 2 NEWS Read More OUR STORY MedDay is a biotechnology company developing new drugs targeting brain metabolism to treat diseases of the nervous system in areas of high unmet need. Read More OUR PIPELINE MedDay currently has candidates in development for the treatment of multiple sclerosis, autism and Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). Read More OUR PLATFORM MedDay utilises its SPECMET research platform to identify new therapeutic targets through a process known as cerebrospinal fluid metabolomic analysis. Read More PRESS RELEASES 26 JUL 2018 MedDay Appoints Industry Leader Christian Chavy as Chief Executive Officer Dr. Frédéric Sedel to Transition to CSO Paris, France, July 26,... Read more 26 JUL 2018 MedDay nomme Christian Chavy, dirigeant reconnu de l’industrie pharmaceutique, au poste de Directeur Général Dr Frédéric Sedel prendra ses fonctions de Directeur scientifique... Read more ABOUT US Who We Are Executive Committee Directors Affiliates Board of Directors Scientific Advisory Board Investors RESEARCH & DEVELOPMENT Pipeline Research Platform Publications SOCIAL Twitter LinkedIn YouTube Send to a Friend SIGN UP Register for news and updates MedDay 24-26 Rue de la Pépinière 75008, PARIS, France Publication Director : Dr Frédéric Sedel © MedDay 2014 - 2018 Sitemap

HOME ABOUT US RESEARCH & DEVELOPMENT FOR PATIENTS NEWS AND EVENTS WHO WE ARE WHO WE ARE EXECUTIVE COMMITTEE DIRECTORS BOARD OF DIRECTORS SCIENTIFIC ADVISORY BOARD INVESTORS MedDay About Us Who We Are At MedDay, we are committed to treating nervous system disorders in areas of high unmet medical need through the elucidation of metabolism pathways in the brain. Our unique clinical and pharmaceutical development expertise in the field of rare inborn errors of metabolism is critical in advancing novel therapeutics for neurological diseases such as multiple sclerosis, autism and Alzheimer’s disease. MedDay was founded in 2011 by Frédéric Sedel, MD, PhD (Chief Executive Officer), a leading neurologist and neuroscientist; and Guillaume Brion, MD (Chief Operating Officer), who has 25 years of experience in drug development and clinical research in the pharmaceutical industry. The company’s most advanced product candidate is MD1003 for the treatment of primary and secondary progressive multiple sclerosis. COM-xxx-001 Revision date: June 2018 ABOUT US Who We Are Executive Committee Directors Affiliates Board of Directors Scientific Advisory Board Investors RESEARCH & DEVELOPMENT Pipeline Research Platform Publications SOCIAL Twitter LinkedIn YouTube Send to a Friend SIGN UP Register for news and updates MedDay 24-26 Rue de la Pépinière 75008, PARIS, France Publication Director : Dr Frédéric Sedel © MedDay 2014 - 2018 Sitemap